Cerus Corporation to Release Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022

Rhea-AI Summary

Cerus Corporation (NASDAQ: CERS) will release its fourth quarter and full-year 2021 financial results on February 22, 2022, post-market close. A conference call will follow at 4:30 P.M. ET, providing insights into the company’s performance and future outlook. Investors can access the live webcast on Cerus’ Investor Relations page or by calling U.S. (866) 235-9006 or international (631) 291-4549.

Additionally, a replay will be available post-call through March 8, 2022.

Positive

• The INTERCEPT Blood System for platelets and plasma has both CE mark and FDA approval.
• Cerus aims to be a preeminent global blood products company, indicating strong market ambitions.

Negative

• None.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on Cerus’ website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 8851919. The replay will be available approximately three hours after the call through March 8, 2022.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005426/en/

Matt Notarianni – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When will Cerus Corporation announce its financial results?

Cerus Corporation will announce its financial results on February 22, 2022.

What time is the Cerus Corporation conference call scheduled?

The conference call is scheduled for 4:30 P.M. ET on February 22, 2022.

How can I access the Cerus Corporation conference call?

You can access the conference call by dialing (866) 235-9006 for U.S. callers or (631) 291-4549 for international callers.

Is there a replay available for the Cerus Corporation call?

Yes, a replay will be available until March 8, 2022.

What is the significance of INTERCEPT Blood System?

The INTERCEPT Blood System is both CE mark and FDA approved, ensuring safe blood components.